Day: November 10, 2025

TTEC shares 5 CX trends that will define winners in 2026AUSTIN, Texas, Nov. 10, 2025 (GLOBE NEWSWIRE) — The future of customer experience is moving at lightning speed — and there’s no rewind button. TTEC Holdings, Inc. (NASDAQ: TTEC), a leading global CX (customer experience) technology and services innovator for AI-enhanced CX, today released its annual trends report, CX Trends 2026: Fast-Forward, spotlighting five critical shifts reshaping how organizations must engage customers in the year ahead. “The world isn’t slowing down,” said Ken Tuchman, chairman and chief executive officer of TTEC. “Technology is evolving, customer expectations are rising and brands that stay stuck in the past will lose customer satisfaction, revenue, and loyalty by the day. Our 2026 trends report shows that brands that integrate...

OCALA, Fla., Nov. 10, 2025 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today detailed a recent abstract containing data from the completed Phase 2 advanced recurrent ovarian cancer clinical study utilizing Ampligen (rintatolimod), which was presented at the 40th Annual SITC Meeting on November 7, 2025, at National Harbor, MD. Platinum-sensitive patients with measurable peritoneal disease were eligible for combination therapy with up to six treatment cycles at 3-week intervals of intraperitoneal cisplatin, intravenous pembrolizumab (also known as Merck’s Keytruda) and intraperitoneal Ampligen. Of the 27 patients included in the trial, 24 were evaluable for response and of those 24 there were 5 patients with complete response and 7 patients with partial response, for an Objective Response...

Over-Allotment Option Exercised in Full  THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. TORONTO, Nov. 10, 2025 (GLOBE NEWSWIRE) — Xtract One Technologies Inc. (TSX: XTRA) (OTCQX: XTRAF) (FRA: 0PL) (“Xtract One” or the “Company”) announces that it has closed its previously announced “bought deal” public offering (the “Offering”) conducted by a syndicate of underwriters led by Stifel Canada (the “Underwriters”). Pursuant to the Offering, the Company issued an aggregate of 15,334,100 units (the “Units”) at a price of $0.75 per Unit for aggregate gross proceeds of $11,500,575.00, which includes the full exercise of the over-allotment option granted to the Underwriters. Each Unit consists of one common share...

Initial Investment of $1 Million Received from Hexstone Capital LLC Upon Closing MELBOURNE, Australia, Nov. 10, 2025 (GLOBE NEWSWIRE) — Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing new treatments for patients suffering from recurrent and metastatic cancer, today announced that it has entered into a securities purchase agreement with Hexstone Capital LLC (“Hexstone”), a family office that has invested in a significant number of Digital Asset Treasury (DAT) companies across a range of digital assets including BTC, ETH, SOL, DOGE, ATH, OG, and INJ. The agreement is for a private placement of up to $100 Million in convertible preferred stock and will be deployed to support its digital asset acquisition strategy and accelerate the Company’s R&D pipeline,...

Move leverages the Company’s expertise in regulated materials to capture opportunities in sustainable, high-growth consumer markets Spring Branch, TX, Nov. 10, 2025 (GLOBE NEWSWIRE) — Callan JMB Inc. (NASDAQ: CJMB) (“Callan JMB” or the “Company”), an integrative logistics company serving healthcare and emergency management sectors through fulfillment, storage, monitoring, and cold chain logistics, today announced the expansion of its reclamation operations into the food sampling industry. This move is part of Callan JMB’s multi-variant strategic growth initiative designed to extend its proven compliance-driven model into adjacent, high-growth markets. Building on a long history of excellence in pharmaceutical and regulated material logistics, Callan JMB is applying its expertise in product integrity, recall readiness, and traceability...

After Decades of Global Failures, Kraig Poised to Deliver First High-Performance Recombinant Breakthrough DENVER, Nov. 10, 2025 (GLOBE NEWSWIRE) — 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and information, reports that, after decades of scientific ambition and hundreds of millions of dollars invested worldwide, Kraig Biocraft Laboratories (OTCQB: KBLB), the undisputed global leader in the development and commercialization of spider silk, appears to be on the verge of achieving what no other company or country has been able to accomplish: the commercial delivery of high-performance recombinant spider silk. In the opinion of 24/7 Market News, Kraig Labs’ imminent shipments of spider silk fiber and fabric samples to fashion and performance textile partners mark a historic...

The Company’s operating loss declined by 44% year-over-year, reflecting its continued laser focus on relentless execution and progress in operational excellence Continued progress with lead program, ERNA-101, toward first-in-human Phase 1 study in platinum-resistant ovarian cancer (PROC), anticipated in H2 2026 CAMBRIDGE, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) — Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced its financial results for the three- and nine-month periods ended September 30, 2025, and highlighted its continued operational execution. Recent HighlightsAnnounced a cell therapy manufacturing partnership to advance ERNA-101 toward clinical trials in ovarian cancer Presented new positive data of ERNA-101 for PROC in ASCO-2025,...